SG11201803781XA - Treatment of retinal degeneration using progenitor cells - Google Patents
Treatment of retinal degeneration using progenitor cellsInfo
- Publication number
- SG11201803781XA SG11201803781XA SG11201803781XA SG11201803781XA SG11201803781XA SG 11201803781X A SG11201803781X A SG 11201803781XA SG 11201803781X A SG11201803781X A SG 11201803781XA SG 11201803781X A SG11201803781X A SG 11201803781XA SG 11201803781X A SG11201803781X A SG 11201803781XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cells
- progenitor cells
- pennsylvania
- johnson
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 title abstract 5
- 201000007737 Retinal degeneration Diseases 0.000 title abstract 3
- 230000004258 retinal degeneration Effects 0.000 title abstract 3
- 210000004027 cell Anatomy 0.000 abstract 4
- 230000002207 retinal effect Effects 0.000 abstract 2
- 230000002068 genetic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 108091008695 photoreceptors Proteins 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau R.:54i (43) International Publication Date ..... ....r .„,,,i 8 June 2017 (08.06.2017) IN I PO I PCT ID Hit (10) WO International 2017/095991 111111111111111111111111111111111111111111111111111111111111111111111111111111 Publication Al Number (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 5/071 (2010.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/US2016/064336 DO, DZ, EC, EE, EG, ES, FE GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 1 December 2016 (01.12.2016) KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 62/263,463 4 December 2015 (04.12.2015) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: JANSSEN BIOTECH, INC. [US/US]; kind of regional protection available): ARIPO (BW, GH, 800/850 Ridgeview Drive, Horsham, Pennsylvania 19044 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (US). TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors: HARRIS, Ian; 1400 McKean Road, Spring TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, House, Pennsylvania 19477 (US). CAO, Jing; 1400 McK- LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, can Road, Spring House, Pennsylvania 19477 (US). DE- SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, JNEKA, Nadine Sophia; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: (74) Agents: SHIRTZ, Joseph F. et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jer- — as to applicant's entitlement to apply for and be granted a sey 08933 (US). patent (Rule 4.170) [Continued on next page] (54) Title: TREATMENT OF RETINAL DEGENERATION USING PROGENITOR CELLS (57) : Methods and compositions for treating and re- ducing retinal degeneration using progenitor cells and condi- from tioned media progenitor cells, such as postpartum-de- **** rived cells are disclosed. Genetic factors and receptors ex - I I * * pressed by the progenitor cells that aid in protection of retinal 100 ' . cells and inhibition of apoptosis of retinal cells such as ****n.s. cells are also disclosed. photoreceptor 171) > 80- a) co to • 60- o , 0 40 0 11111 • 1111 E F 20- Nk . Vi kG 0 1\ e lk GO GS G. GO 54 S4 o_0 5 a 0S7 0 _0 k e 03S 4 Q\" \) \ ` - ‘Y` - \t - l‘ ikk 1\ 9- 0 9- \0\" \t\"(` ` vr ve \ ** 0 11 / 4 - .0 1 / 4 4 ‘.4 ‘.0 ‘ 1,4 0.9 ., cp , e s , o 1 / 4 2,S e\ 0 ,,,,, ,-, .4t • CO S3 : 3 •CA 13 •0 \ te t ee S %N. aG cy ci, .#0 . 0 0 0 __ %., 40 3e2P s y r car Cr .0 * s yew Il O\ O\ un FIG. 1 C\ C IN Il C ei O WO 2017/095991 Al MIDEDIMOMMIDIROMMIMINECIMMOVOIMIE — as to the applicant's entitlement to claim the priority of — with sequence listing part of description (Rule 5.2(a)) the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562263463P | 2015-12-04 | 2015-12-04 | |
PCT/US2016/064336 WO2017095991A1 (en) | 2015-12-04 | 2016-12-01 | Treatment of retinal degeneration using progenitor cells |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201803781XA true SG11201803781XA (en) | 2018-06-28 |
Family
ID=58797699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201803781XA SG11201803781XA (en) | 2015-12-04 | 2016-12-01 | Treatment of retinal degeneration using progenitor cells |
Country Status (15)
Country | Link |
---|---|
US (1) | US20170157179A1 (en) |
EP (1) | EP3384009A4 (en) |
JP (1) | JP2019501888A (en) |
KR (1) | KR20180088713A (en) |
CN (1) | CN108291199A (en) |
AR (1) | AR106913A1 (en) |
AU (1) | AU2016365312A1 (en) |
BR (1) | BR112018011278A2 (en) |
CA (1) | CA3007198A1 (en) |
MX (1) | MX2018006729A (en) |
PH (1) | PH12018501045A1 (en) |
RU (1) | RU2018122461A (en) |
SG (1) | SG11201803781XA (en) |
TW (1) | TW201729819A (en) |
WO (1) | WO2017095991A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8790637B2 (en) | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
KR102224115B1 (en) | 2020-01-10 | 2021-03-09 | 경북대학교병원 | Structure for retinal cell culture using 3D bioprinting and Uses thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6001855A (en) * | 1998-01-02 | 1999-12-14 | Hoffman-La Roche Inc. | Thiazole derivatives |
US20010041670A1 (en) * | 1999-12-06 | 2001-11-15 | Ronit Simantov | Thrombospondin-binding region of histidine-rich glycoprotein and method of use |
BR0211604A (en) * | 2001-08-01 | 2004-08-24 | Merck Patent Gmbh | Integrin inhibitors for the treatment of eye disease |
US8790637B2 (en) * | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
EP1641915B1 (en) * | 2003-06-27 | 2016-07-27 | DePuy Synthes Products, Inc. | Repair and regeneration of ocular tissue using postpartum-derived cells |
CA2705541C (en) * | 2007-11-15 | 2018-09-11 | The Feinstein Institute For Medical Research | Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using mfg-e8 |
JP6106159B2 (en) * | 2011-05-09 | 2017-03-29 | アレグロ ファーマシューティカルズ インコーポレイテッドAllegro Pharmaceuticals,Inc. | Pharmaceutical composition comprising RG-cysteic acid peptide |
WO2013184976A2 (en) * | 2012-06-06 | 2013-12-12 | Northwestern University | Compositions and methods for antigen-specific tolerance |
MX2017007953A (en) * | 2014-12-16 | 2018-02-09 | Janssen Biotech Inc | Treatment of retinal degeneration using progenitor cells. |
-
2016
- 2016-12-01 CA CA3007198A patent/CA3007198A1/en not_active Abandoned
- 2016-12-01 BR BR112018011278A patent/BR112018011278A2/en not_active Application Discontinuation
- 2016-12-01 AU AU2016365312A patent/AU2016365312A1/en not_active Abandoned
- 2016-12-01 SG SG11201803781XA patent/SG11201803781XA/en unknown
- 2016-12-01 KR KR1020187018529A patent/KR20180088713A/en unknown
- 2016-12-01 CN CN201680071080.7A patent/CN108291199A/en active Pending
- 2016-12-01 WO PCT/US2016/064336 patent/WO2017095991A1/en active Application Filing
- 2016-12-01 MX MX2018006729A patent/MX2018006729A/en unknown
- 2016-12-01 EP EP16871469.9A patent/EP3384009A4/en not_active Withdrawn
- 2016-12-01 JP JP2018528794A patent/JP2019501888A/en active Pending
- 2016-12-01 US US15/366,599 patent/US20170157179A1/en not_active Abandoned
- 2016-12-01 RU RU2018122461A patent/RU2018122461A/en not_active Application Discontinuation
- 2016-12-02 TW TW105139990A patent/TW201729819A/en unknown
- 2016-12-05 AR ARP160103730A patent/AR106913A1/en unknown
-
2018
- 2018-05-16 PH PH12018501045A patent/PH12018501045A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20170157179A1 (en) | 2017-06-08 |
MX2018006729A (en) | 2018-11-09 |
JP2019501888A (en) | 2019-01-24 |
EP3384009A4 (en) | 2019-06-12 |
WO2017095991A1 (en) | 2017-06-08 |
EP3384009A1 (en) | 2018-10-10 |
CN108291199A (en) | 2018-07-17 |
BR112018011278A2 (en) | 2018-11-21 |
RU2018122461A (en) | 2020-01-13 |
AR106913A1 (en) | 2018-02-28 |
KR20180088713A (en) | 2018-08-06 |
PH12018501045A1 (en) | 2019-01-28 |
TW201729819A (en) | 2017-09-01 |
AU2016365312A1 (en) | 2018-05-24 |
CA3007198A1 (en) | 2017-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201803593QA (en) | Engineered nucleic-acid targeting nucleic acids | |
SG11201809649WA (en) | Macromolecule analysis employing nucleic acid encoding | |
SG11201804161VA (en) | Compositions comprising bacterial strains | |
SG11201908391XA (en) | Methods for modulating an immune response | |
SG11202000274RA (en) | Oligonucleotide compositions and methods thereof | |
SG11201810179RA (en) | Novel crispr enzymes and systems | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
SG11201806398YA (en) | Optimized factor viii genes | |
SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201908560SA (en) | Heterocyclic compounds useful as dual atx/ca inhibitors | |
SG11201807269PA (en) | Filamentous fungal biomats, methods of their production and methods of their use | |
SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
SG11201809700YA (en) | Gdf15 fusion proteins and uses thereof | |
SG11201906319XA (en) | Compositions and methods for the depletion of cd137+ cells | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
CA3025288C (en) | Reduced misting alkaline and neutral cleaning, sanitizing, and disinfecting compositions via the use of high molecular weight water-in-oil emulsion polymers | |
SG11201811554SA (en) | Antisense oligonucleotides for modulating htra1 expression | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201809531SA (en) | BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF | |
SG11201803918VA (en) | Production of steviol glycosides in recombinant hosts |